Good Investment
We believe this name makes for a good investment for a long time horizon. She has quite a few drugs in the pipeline in various phase with varying purposes. NKTR's long term debt is almost half that of the industry average. The recent partnerships that she has formed with other drug companies may improve her financials via royalties; giving her a positive EPS hopefully. If her lead drug Onzeald (a treatment for advanced breast cancer) fairs well in phase III there will most likely be a regulatory filing in the US.
For you swing traders she may exhibit more upside as she seems to have found support at the $17.55 level and if this is held anything in between there and $21.50 is obtainable in the short run. This follows a healthy pullback from her rally at the beginning of this year.
We wish you the best options and opportunities.
Want to know the lowest risk way to play this name? Go to www.emeraldchasellc.com or hit us on Messenger
